In this session, new therapeutic advances in both the clinical & basic science world will be presented. Clinicians & basic scientists alike will find value in the discussion about novel approaches to treat CF lung disease in addition to the presentation of outcome measures appropriate for young children.
Identify the latest advances in treatment focused on inflammation, gene therapy & mesenchymal stem cells currently under study for CF.
Describe the applicability of lung clearance index as an outcome measure for lung disease progression in young children.
Assess the impact ivacaftor & hormone fluctuations have on the trajectory of disease progression.